- Home
- AG vs BEAM Comparison
AG vs BEAM Comparison
Compare AG & BEAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AG
- BEAM
- Stock Information
- Founded
- AG 1979
- BEAM 2017
- Country
- AG Canada
- BEAM United States
- Employees
- AG N/A
- BEAM N/A
- Industry
- AG Precious Metals
- BEAM Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- AG Basic Materials
- BEAM Health Care
- Exchange
- AG Nasdaq
- BEAM Nasdaq
- Market Cap
- AG 4.1B
- BEAM 1.6B
- IPO Year
- AG N/A
- BEAM 2020
- Fundamental
- Price
- AG $8.46
- BEAM $19.94
- Analyst Decision
- AG Buy
- BEAM Strong Buy
- Analyst Count
- AG 2
- BEAM 11
- Target Price
- AG $8.75
- BEAM $48.90
- AVG Volume (30 Days)
- AG 27.3M
- BEAM 2.0M
- Earning Date
- AG 07-31-2025
- BEAM 08-05-2025
- Dividend Yield
- AG 0.23%
- BEAM N/A
- EPS Growth
- AG N/A
- BEAM N/A
- EPS
- AG N/A
- BEAM N/A
- Revenue
- AG $698,532,000.00
- BEAM $63,578,000.00
- Revenue This Year
- AG $68.65
- BEAM N/A
- Revenue Next Year
- AG $9.36
- BEAM $8.82
- P/E Ratio
- AG N/A
- BEAM N/A
- Revenue Growth
- AG 33.60
- BEAM N/A
- 52 Week Low
- AG $4.43
- BEAM $13.53
- 52 Week High
- AG $8.74
- BEAM $35.25
- Technical
- Relative Strength Index (RSI)
- AG 64.22
- BEAM 68.51
- Support Level
- AG $8.22
- BEAM $16.59
- Resistance Level
- AG $8.57
- BEAM $17.38
- Average True Range (ATR)
- AG 0.32
- BEAM 1.07
- MACD
- AG -0.05
- BEAM 0.35
- Stochastic Oscillator
- AG 69.23
- BEAM 90.73
About AG First Majestic Silver Corp. (Canada)
First Majestic Silver Corp is engaged in the production, development, exploration, and acquisition of mineral properties with a focus on silver and gold production in North America. It owns three producing mines in Mexico consisting of the San Dimas Silver/Gold Mine, the Santa Elena Silver/Gold Mine, and the La Encantada Silver Mine.
About BEAM Beam Therapeutics Inc.
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States.